Neoadjuvant Pembrolizumab Plus Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma

NCT05302011 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

28

Enrollment

OTHER

Sponsor class

Conditions

Esophageal Squamous Cell Carcinoma

Interventions

DRUG: Pembrolizumab
DRUG: Carboplatin or Cisplatin
DRUG: Docetaxel

Sponsor

Peking Union Medical College Hospital